<SEC-DOCUMENT>0001193125-23-147097.txt : 20230517
<SEC-HEADER>0001193125-23-147097.hdr.sgml : 20230517
<ACCEPTANCE-DATETIME>20230517170103
ACCESSION NUMBER:		0001193125-23-147097
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230516
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230517
DATE AS OF CHANGE:		20230517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38944
		FILM NUMBER:		23932619

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-487-6488

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d503970d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:akro="http://www.akerotx.com/20230516" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-05-16_to_2023-05-16">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-05-16_to_2023-05-16">0001744659</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="akro-20230516.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-05-16_to_2023-05-16"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001744659</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-16</xbrli:startDate> <xbrli:endDate>2023-05-16</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-05-16_to_2023-05-16">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt:datemonthdayyearen">May 16, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-05-16_to_2023-05-16">Akero Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-05-16_to_2023-05-16">001-38944</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-05-16_to_2023-05-16">81-5266573</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-05-16_to_2023-05-16">601 Gateway Boulevard</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-05-16_to_2023-05-16">Suite 350</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-05-16_to_2023-05-16">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-05-16_to_2023-05-16">CA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-05-16_to_2023-05-16">94080</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-05-16_to_2023-05-16">(650)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-05-16_to_2023-05-16">487-6488</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-05-16_to_2023-05-16">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-05-16_to_2023-05-16">AKRO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-05-16_to_2023-05-16" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;1.01. Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May 16, 2023, Akero Therapeutics, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into an underwriting agreement (the &#8220;<span style="text-decoration:underline">Underwriting Agreement</span>&#8221;) with Jefferies LLC, as representative of the several underwriters named therein (the &#8220;<span style="text-decoration:underline">Underwriter</span>&#8221;), pursuant to which the Company agreed to issue and sell 5,238,500 shares (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;), to the Underwriter in an underwritten offering at an offering price of $42.00 per share, before deducting underwriting discounts and commissions (the &#8220;<span style="text-decoration:underline">Offering</span>&#8221;). The Offering is expected to close on May 19, 2023, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to the Company from the Offering are expected to be approximately $210.9 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to continue to advance the clinical development of efruxifermin (&#8220;<span style="text-decoration:underline">EFX</span>&#8221;), including the Company&#8217;s ongoing Phase 2b HARMONY trial, its ongoing Phase 2b SYMMETRY trial, an expansion cohort of the SYMMETRY trial, manufacture of drug product for Phase 3 clinical trials, and initiation of its planned Phase 3 SYNCHRONY clinical trial program, with the remainder for working capital and other general corporate purposes. The Company may also use a portion of its net proceeds, together with its existing cash, cash equivalents and marketable securities, to develop, <span style="white-space:nowrap">co-develop,</span> acquire or invest in products that are complementary to EFX to expand its pipeline. However, the Company currently does not have any agreements or commitments to complete any such transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made pursuant to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-3ASR</span> (File <span style="white-space:nowrap">No.&#160;333-256229)</span> (the &#8220;<span style="text-decoration:underline">Registration Statement</span>&#8221;), which was previously filed with the Securities and Exchange Commission and automatically became effective on May&#160;18, 2021, as supplemented by a prospectus supplement dated May 16, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriter, including for liabilities under the&#160;Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP, counsel to the Company, delivered an opinion as to legality of the issuance and sale of the Common Stock in the Offering, a copy of which is attached hereto as Exhibit 5.1 and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May 16, 2023, the Company issued a press release announcing the pricing of the Offering and its entry into the Underwriting Agreement. A copy of the press release is attached to this Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K&#160;as&#160;Exhibit</span> 99.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> and certain of the materials filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the Offering, and expectations regarding our cash runway, use of capital, expenses and other future financial results. The words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as those related to the anticipated closing of the Offering, are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> or the materials furnished or filed herewith, including, without limitation, uncertainties related to market conditions and the completion of the Offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2022 and the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended March&#160;31, 2023, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d503970dex11.htm">Underwriting Agreement, dated as of May 16, 2023, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d503970dex51.htm">Opinion of Goodwin Procter LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d503970dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit&#160;5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d503970dex991.htm">Press Release issued by the Company on May 16, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Date: May 17, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">AKERO THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Cheng</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Cheng, M.D., Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d503970dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Akero Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5,238,500 Shares of Common Stock, par value $0.0001 per share </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">May&nbsp;16, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">several Underwriters
listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Akero Therapeutics, Inc.,
a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representative (the &#147;Representative&#148;), an
aggregate of 5,238,500 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of the Company (the &#147;Shares&#148;). The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the
Shares are referred to herein as the &#147;Stock&#148;. To the extent there are no additional Underwriters listed on Schedule 1 other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and
Underwriters shall mean either the singular or plural as the context requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several
Underwriters concerning the purchase and sale of the Shares, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement</U>. The
Company has prepared and filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities
Act&#148;), a registration statement on Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256229),</FONT> including a prospectus, relating to the Shares. The Company meets the requirements for
use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The proposed offering of the Shares may be made pursuant to General Instruction 1.B.1 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Such registration statement,
as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430
Information&#148;), is referred to herein as the &#147;Registration Statement&#148;; and the related prospectus covering the Shares in the form first used to confirm sales of the Shares (or in the form first made available to the Underwriters by the
Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act) is hereinafter referred to as the &#147;Base Prospectus.&#148; If applicable, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities
Act and the, if applicable, any prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the Base Prospectus, as supplemented by the prospectus
supplement, in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement
pursuant to Rule 462(b) under the Securities Act (the &#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#147;Agreement&#148;) to the Registration Statement, the Base Prospectus or the Prospectus
shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement, the
date of the Base Prospectus or the date of the Prospectus, as the case may be, and any reference to &#147;amend&#148;, &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Base Prospectus or the Prospectus
shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are
deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing
information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): the Registration Statement (including the documents incorporated by reference in the Registration Statement) and each &#147;free-writing prospectus&#148; (as defined
pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 5:30 P.M., New York City time,
on May&nbsp;16, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase of the Shares by the Underwriters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to issue and sell the Shares to the several Underwriters as provided in this
Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $40.32 (the
&#147;Purchase Price&#148;) from the Company the respective number of Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company understands that the Underwriters intend to make an offering of the Shares, and
initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the Shares shall be made by wire transfer in immediately available funds to the account
specified by the Company to the Representative at the offices of Cooley LLP, counsel for the Underwriters, at 55 Hudson Yards, New York, New York 10001-2157, at 10:00 A.M., New York City time, on May&nbsp;19, 2023 or at such other time or place on
the same or such other date, not later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing. The time and date of such payment for the Underwritten Shares is referred to herein as the &#147;Closing
Date.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the Shares to be purchased on the Closing Date shall be made against
delivery to the Representative for the respective accounts of the several Underwriters of the Shares to be purchased on such Closing Date with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery
of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representative shall otherwise instruct. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that the
Representative and the other Underwriters are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the
terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representative nor any other Underwriter is advising the Company or any other person as to any legal,
tax, investment, accounting or regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions
contemplated hereby, and neither the Representative nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representative and the other Underwriters of the Company, the
transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did
not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by
such Underwriter through the Representative expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in
the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Issuer Free Writing Prospectus. </I>Other than
the Registration Statement and the Prospectus, the Company (including its agents and representative, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make,
use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or
its agents and representative (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the
Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representative. Each such Issuer Free
Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and (except as expressly
set forth in such Issuer Free Writing Prospectus) does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and such Issuer Free Writing Prospectus did not, and as of the Closing Date will not,
contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes
no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representative expressly for use in such Issuer Free Writing Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;[Reserved] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;
<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The Company (i)&nbsp;has not engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Statement and Prospectus.</I> The Registration Statement is an &#147;automatic shelf
registration statement&#148; as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no notice of objection of the Commission to the use of such registration
statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no
proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable
effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will
not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or
supplement thereto and as of the Closing Date the Prospectus complied and will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in
conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it
being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Incorporated Documents</I>. The documents incorporated by reference in the Registration
Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a
material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the
Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Financial Statements</I>. The financial
statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects
with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results
of its operations and the changes in its cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#147;GAAP&#148;) applied on a consistent
basis throughout the periods covered thereby, except in the case of any unaudited, interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as
permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the
other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and
presents fairly in all material respects the information shown thereby; and there are no disclosures included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding <FONT
STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the
Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any material change in the capital stock (other than the issuance of shares of Common Stock
upon exercise of stock options or vesting of awards described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus),
short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or
any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its
subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as
a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss or interference with
its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order
or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Organization and Good Standing.</I> The Company and each of its subsidiaries have been duly
organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of
property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the
failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity,
results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the
subsidiaries listed in Exhibit 21 to the Registration Statement. The subsidiaries listed in Schedule 2 to this Agreement are the only significant subsidiaries of the Company. Since inception Akero Securities Corporation, a wholly owned subsidiary of
the Company, has not conducted, and does not currently conduct, any operations, has not had and does not have any employees and has been and is engaged exclusively in buying, selling, dealing in and holding publicly-traded securities on its own
behalf and not as a broker. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Capitalization.</I> The Company has an authorized capitalization
as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Description of Capital Stock&#148;; all the outstanding shares of capital stock of the Company have been duly and validly
authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by
the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or
instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the
issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description
thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been
duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) and are owned directly or indirectly by the
Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock Options. </I>With respect to the stock options (the &#147;Stock Options&#148;) granted
pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal
Revenue Code of 1986, as amended (the &#147;Code&#148;) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary
corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and
the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, and (iv)&nbsp;each such grant was properly
accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. The
Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement of material
information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver
this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has
been duly and validly taken. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Underwriting Agreement. </I>This Agreement has
been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>The Shares. </I>The Shares to
be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all
material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly and validly
waived or satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<I>Listing. </I>The Shares are listed on the Nasdaq Global Select Market
(&#147;Nasdaq Market&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<I>Description of the Underwriting Agreement.</I> This Agreement
conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in
violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or
any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the
issuance and sale of the Shares and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of
the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or assets of the Company or
any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to
which any of the property, right or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational
documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of
clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Consents Required.</I> No consent, filing, approval, authorization, order, license,
registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the
consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the
Financial Industry Regulatory Authority, Inc. (&#147;FINRA&#148;), Nasdaq and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<I>Legal Proceedings.</I> There are no legal,
governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the
Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; no such Actions
are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in
the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or
other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the
Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;<I>Independent Accountants</I>. Deloitte&nbsp;&amp; Touche LLP, who has certified certain financial
statements of the Company and its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company
Accounting Oversight Board (United States) and as required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<I>Title to
Real and Personal Property</I>. The Company and its subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property
and assets that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially
interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;<I>Title to Intellectual Property</I>. The Company and its subsidiaries own, or possess valid and
enforceable licensed rights to use, all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights, Internet domain names,
copyrights, works of authorship, licenses, proprietary information and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures)
necessary for the conduct of their respective businesses as currently conducted and as proposed to be conducted (collectively, &#147;Intellectual Property&#148;), and, to the Company&#146;s knowledge, the conduct of their respective businesses does
not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or
unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. The Company and its subsidiaries have not received any notice of any claim of infringement, misappropriation
with any intellectual property rights of another, and the Company is unaware of any facts which would form a reasonable basis for any such notice or claim. To the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any
Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Pricing Disclosure Package and the Prospectus (&#147;Disclosure Documents&#148;) as owned by or licensed to the Company or its subsidiaries; and (ii)&nbsp;there is no infringement by third
parties of any Intellectual Property. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by
others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity,
enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or its subsidiaries infringe,
misappropriate, or otherwise violate, or would, upon the commercialization of any product or service described in the Disclosure Documents as under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of
others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual
Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the
Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention
assignment agreements and invention assignments with their employees, and to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention
assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the
basis of such violation relates to such employee&#146;s employment with the Company. To the Company&#146;s knowledge, the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United
States patents and patent applications included in the Intellectual Property have been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with. None of the Company owned Intellectual
Property or technology (including information technology and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding
on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any persons. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;<I>Trade Secrets</I>. The Company and its subsidiaries have taken reasonable and customary actions
to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including material confidential source code, ideas, research and development information, <FONT
STYLE="white-space:nowrap">know-how,</FONT> formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and
information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and, to the knowledge of the Company, there has been no unauthorized use or disclosure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;<I> IT Assets</I>. Except as could not reasonably be expected to have a Material Adverse Effect
(i)&nbsp;the computers, software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the Company or its subsidiaries (excluding any public networks) (collectively, the
&#147;IT Assets&#148;) operate and perform as is necessary for the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be conducted as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, and (ii)&nbsp;such IT Assets are not infected by viruses, disabling </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
code or other harmful code. The Company and its subsidiaries have at all times implemented and maintained all reasonably necessary controls, policies, procedures, and safeguards to maintain and
protect their confidential information and the integrity, continuous operation, redundancy and security of all IT Assets and data (including all Sensitive Data (defined below) sensitive, confidential or regulated data (&#147;Confidential Data&#148;)
used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other
person, nor any incidents under internal review or investigations relating to the same. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;<I>Data
Privacy and Security Laws</I>. The Company and its subsidiaries and, to the Company&#146;s knowledge, their respective agents and subcontractors, are, and at all prior times were, in compliance in all material respects with all applicable state,
federal, and international data privacy and data security laws, regulations, and related rules and requirements, including without limitation the Health Insurance Portability and Accountability Act of 1996 and the HITECH Act (collectively
&#147;HIPAA&#148;), the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679) (collectively, the &#147;Privacy Laws&#148;). To address compliance with the Privacy Laws, the Company and its subsidiaries have in place,
comply with, and take commercially reasonable steps to achieve compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and transfer of
Personal Data (the &#147;Policies&#148;). &#147;Personal Data&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax
identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any other piece of information that identifies such natural person and is defined in or addressed by
Privacy Laws. At all times, the Company and its subsidiaries have made all disclosures to users or customers required by applicable Privacy Laws, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company,
been inaccurate or in violation of any applicable Privacy Laws. The Company further certifies that (a)&nbsp;neither it nor any subsidiary at any time: (i)&nbsp;has received receive written notice of any actual or potential liability, including, but
not limited to security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of its Sensitive Data (defined below) owned or controlled by the Company or its subsidiaries, under or relating to, or actual or
potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;other than pursuant to its ongoing compliance efforts in the ordinary course of
business, is currently conducting, subject to, or paying, in whole or in part, any material investigation, remediation, or other corrective action resulting from the Company&#146;s or its subsidiaries&#146;
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Privacy Law; or (iii)&nbsp;is a party to any order, decree, settlement agreement, or judgment from a governmental entity that imposes any obligation or liability under any Privacy Law;
and (b)&nbsp;it is not aware of any specific events rendering any of the foregoing reasonably likely to occur. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Complaints</I>. There is no complaint or audit, proceeding, investigation (formal or
informal) or claim currently pending against the Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer&#146;s use of the products or services of the Company) by any state Attorney General or
related office, the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (&#147;HHS&#148;), or any similar authority in any jurisdiction other than the United States or any other governmental
entity, or by any person in respect of the collection, use or disclosure of Sensitive Data (defined below) by the Company or its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is
threatened. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<I>FDA Compliance</I>. The Company: (A)&nbsp;is
and at all times has been in material compliance with all statutes, rules or regulations of the U.S. Food and Drug Administration (&#147;<U>FDA</U>&#148;) and other comparable governmental entities applicable to the ownership, testing, development,
manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (&#147;Applicable
Laws&#148;); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any comparable governmental entity alleging or asserting material noncompliance with any
Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#147;Authorizations&#148;); (C) possesses all material
Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from the FDA or any comparable governmental entity or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no
knowledge that the FDA or any comparable governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;has not received notice that the FDA or any comparable
governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any comparable governmental entity is considering such action; and (F)&nbsp;has
filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<I>Studies, Tests and Preclinical and Clinical Trials</I>. The studies, tests and preclinical and
clinical trials conducted by or on behalf of the Company, to the Company&#146;s knowledge, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to
accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any applicable rules, regulations
and policies of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are,
to the Company&#146;s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the Pricing
Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the
Prospectus, the Company has not received any notices or correspondence from the FDA or any comparable governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of
the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Health Care Laws</I>. The
Company and its subsidiaries, and to the Company&#146;s knowledge their respective officers, directors, employees and agents, are, and at all times have been, in compliance in all material respects with all Health Care Laws, to the extent applicable
to the business of the Company and its subsidiary. For purposes of this Agreement, &#147;Health Care Laws&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal,
state, local and foreign health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. Civil False Claims Act (31 U.S.C.
Section&nbsp;3729 et seq.), the criminal False Statements Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286, 287, 1035, 1347, and 1349 the health care fraud criminal provisions under HIPAA, the
civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusions law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C <FONT
STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and the laws governing U.S. government funded or sponsored healthcare programs; (iii)&nbsp;similar local, state, federal, national, supranational and foreign laws the directives and
regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof; and (iv)&nbsp;all other local, state, federal, national and supranational laws applicable to the regulation of
the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or
distributed by or for the Company or any of its Subsidiaries. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action threatened. The Company, and to the Company&#146;s knowledge, its subsidiaries, have filed, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on
the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company, any of its subsidiaries, nor, to the Company&#146;s knowledge, any of their respective employees, officers, directors, or
agents is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its
subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is
subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among
the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be
described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale
of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity
&#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<I>Taxes.</I> The Company and its subsidiaries
have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof except for taxes being contested in good faith and for which reserves in accordance with GAAP have been taken; and
except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its
subsidiaries or any of their respective properties or assets that would individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<I>Licenses and Permits.</I> To the Company&#146;s knowledge, the Company and its subsidiaries
possess all licenses, certificates, permits and other authorizations, other than with respect to its Intellectual Property, issued by, and have made all declarations and filings with, the appropriate and applicable federal, state, local or foreign
governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and
the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has received notice of any revocation or
modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course, except where such revocation, modification or
nonrenewal would not reasonably be expected to have a Material Adverse Effect. To the Company&#146;s knowledge, no party granting any such licenses, certificates, permits and other authorizations has taken any action to limit, suspend or revoke the
same in any material respect. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required and
that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) as
required for maintenance of their licenses, certificates, permits and other authorizations that are necessary for the conduct of their respective businesses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any
of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146;
principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining
agreement to which it is a party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<I>Certain Environmental Matters. </I>(i)&nbsp;The Company
and its subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally
enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y)
have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not
received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic
substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii)&nbsp;there are no costs or liabilities associated with Environmental
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect; and (iii)&nbsp;(x) there is no proceeding that is pending, or that is known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is
also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with
Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital
expenditures, earnings or competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<I>Hazardous Materials</I>. There has been no storage, generation, transportation, use, handling,
treatment, Release or threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts
or omissions the Company or any of its subsidiaries is or would reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or any of its subsidiaries, or at, on,
under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation or
liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Hazardous Materials&#148; means any material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or
constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally occurring radioactive materials, brine,
and drilling mud, regulated or which can give rise to liability under any Environmental Law. &#147;Release&#148; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping,
disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of
Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under
common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as
amended (the &#147;Code&#148;)) would have any liability (each, a &#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA
and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative
exemption; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding
standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of
ERISA) and no Plan that is a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the
fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur;
(vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the
Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary
course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur:
(A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the
amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase in the Company and its subsidiaries&#146; &#147;accumulated post-retirement
benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company and its subsidiaries&#146; most recently completed
fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<I>Disclosure Controls</I>. The Company and its subsidiaries maintain an effective system of
&#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information
required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and
procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out
evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accounting Controls.</I> The Company and its subsidiaries maintain systems of &#147;internal
control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their
respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general
or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v)&nbsp;interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with
the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses or significant deficiencies in the Company&#146;s
internal controls over financial reporting. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation
of internal controls over financial </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;to
the best knowledge of the Company, any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<I>eXtensible Business Reporting Language.</I> The interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable
thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<I>Insurance. </I>The Company and its subsidiaries have insurance covering their
respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by companies engaged in the same or similar
business and which the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent
of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director,
officer, or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or
benefit to any foreign or domestic government or regulatory official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any
of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation
implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or
anti-corruption laws; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or
improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and
anti-corruption laws. Neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything
else of value, to any person in violation of any applicable anti-corruption laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company and its
subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money
laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued,
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
administered or enforced by any governmental or regulatory agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or
governmental or regulatory agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries,
directors, officers or employees, nor, to the knowledge of the Company, any agent, or affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is an individual or entity (&#147;Person&#148;) that is, or
is owned or controlled by one or more Persons that are (i)&nbsp;currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S.
Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, Her
Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), or (ii)&nbsp;located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without
limitation, Cuba, Iran, North Korea, Syria, and the Crimea, Donetsk People&#146;s Republic, and Luhansk People&#146;s Republic regions of Ukraine (each, a &#147;Sanctioned Country&#148;). The Company will not directly or indirectly use the proceeds
of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person
that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation
by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since the Company&#146;s inception, the Company and its subsidiaries have not knowingly engaged in and are
not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited,
directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or similar ownership interest,
from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any
contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in
connection with the offering and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Registration Rights</I>. Except as
described in the Registration Statement, the Pricing Disclosure Packages and the Prospectus, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the
filing of the Registration Statement with the Commission or the issuance and sale of the Shares, other than those rights that have been duly and validly waived. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization.</I> Neither the Company nor
any of its subsidiaries or affiliates has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;<I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares nor the application of
the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other
regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy)&nbsp;&nbsp;&nbsp;&nbsp;<I>Forward-Looking Statements.</I> No forward-looking
statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been
made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(zz)</I>&nbsp;&nbsp;&nbsp;&nbsp;<I>Statistical and Market Data.</I> Nothing has come to the attention of the Company that
has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources
that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;<I>Sarbanes-Oxley Act</I>. There is
and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as
amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;<I>Status under the Securities Act</I>. At the time of filing the Registration Statement and any
post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the
Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities,
convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under
the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd)&nbsp;&nbsp;&nbsp;&nbsp;<I>Cybersecurity; Data Protection</I>. (A)&nbsp;There has been no security
breach or incident, unauthorized access or disclosure, or other compromise of or relating to the Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites,
applications, technology, data and databases (including the data and information of their respective customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and its subsidiaries, Sensitive
Data (defined below) and any such data processed or stored by third parties on behalf of the Company and its subsidiaries) collectively, &#147;IT Systems and Data&#148;); (B) The IT Systems and Data are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and the subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other
corruptants; and (C)&nbsp;the Company and its subsidiaries have implemented and maintained appropriate controls, policies, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
procedures, and administrative, technical, and physical safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security
of all IT Systems and Data (including all Personal Data, sensitive, confidential or regulated data (&#147;Sensitive Data&#148;)) reasonably consistent with industry standards and practices or as required by applicable regulatory standards. The
Company and its subsidiaries have been and are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal
policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee)&nbsp;&nbsp;&nbsp;&nbsp;<I>WKSI</I>. The Company is a &#147;well-known seasoned issuer&#148; as defined in Rule 405 of the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Agreements of the Company</U>. The Company covenants and agrees with each
Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Required Filings.</I> The Company will file the final Prospectus with the
Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; the Company will file
promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for
so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the
Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representative may reasonably request. The Company will pay the registration fee for this
offering within the time period required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery of Copies.</I> The Company will deliver, upon request and without charge, (i)&nbsp;to
the Representative, four signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to
each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus
(including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representative may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148;
means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule
172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before preparing, using,
authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the
Representative and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file
any such proposed amendment or supplement to which the Representative reasonably object. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice to the Representative.</I> The Company
will advise the Representative promptly, and confirm such advice in writing (which advice may be delivered via electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has
been filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the
Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any
additional information including, but not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the
Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any of the Pricing Disclosure Package, the Prospectus or the initiation or
threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the
Pricing Disclosure Package, or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact or necessary in order to make the statements therein, in the
light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect
to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its best efforts to prevent the issuance of any such order
suspending the effectiveness of the Registration Statement, preventing or suspending the use of any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Shares and, if any such order is issued, will use its
reasonable best efforts to obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Ongoing
Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or
supplement the Prospectus to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as
the Representative may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or
supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will
comply with law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or
(ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission
(to the extent required) and furnish to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Underwriters and to such dealers as the Representative may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and
incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a
purchaser, be misleading or so that the Pricing Disclosure Package will comply with law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue Sky Compliance.</I> The Company will qualify the Shares for offer and sale under the
securities or Blue Sky laws of such jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be
required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such
jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Earnings Statement. </I>The Company will make generally available to its securityholders and the
Representative as soon as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with
the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement, it being understood and agreed that such earning statement shall be deemed to have been made available by
the Company if the Company is in compliance with its reporting obligations pursuant to the Exchange Act, if such compliance satisfies the conditions of Rule 158, and if such earnings statement is made available on the Commission&#146;s Electronic
Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Clear Market.</I> For a
period of 90 days after the date of the Prospectus, the Company will not, and will not publicly disclose an intention to, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act (other than registration
statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act relating to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (as defined below) granted or to be granted pursuant to the terms of any Company Stock
Plan disclosed in the Pricing Disclosure Package relating to any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock <FONT STYLE="white-space:nowrap">(&#147;Lock-Up</FONT> Securities&#148;), or (ii)&nbsp;enter
into any swap, hedging or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be
settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Jefferies LLC, other than (A)&nbsp;the Shares to be sold hereunder, (B)&nbsp;any shares of Stock issued upon the exercise of options
outstanding on the date hereof, described in the Registration Statement, the Pricing Disclosure Package, the Prospectus, or, in each case, any document incorporated by reference therein, and issued under Company Stock Plans disclosed in the
Registration Statement, the Pricing Disclosure Package, the Prospectus, or in each case, any document incorporated by reference therein; provided that each newly appointed director or executive officer that is a recipient of any such shares of Stock
shall deliver (if it has not previously delivered) a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement to the Representative substantially in the form of Exhibit A hereto, and such shares of Stock will be subject to the terms of
such <FONT STYLE="white-space:nowrap">lock-up,</FONT> (C)&nbsp;the grant by the Company of awards under Company Stock Plans as disclosed in the Registration Statement, the Pricing Disclosure Package, the Prospectus, or, in each case, any document
incorporated by reference therein; provided that each newly appointed director or executive officer that is a recipient of any such awards shall deliver (if it has not previously </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
delivered) a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement to the Representative substantially in the form of Exhibit A hereto, and such awards will be subject to the
terms of such <FONT STYLE="white-space:nowrap">lock-up,</FONT> (D)&nbsp;up to 5% of the Company&#146;s outstanding securities issued by the Company in connection with mergers, acquisitions or commercial or strategic transactions provided that each
newly appointed director or executive officer that is a recipient execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the remainder of the Restricted Period in the form of Exhibit A hereto, (E)&nbsp;the filing by the Company of
any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to a Company Stock Plan described in the Registration Statement, the Pricing Disclosure Package, the Prospectus, or, in each case,
any document incorporated by reference therein, (F)&nbsp;any shares of Stock sold in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offerings pursuant to that Open Market Sale Agreement, by
and between the Company and Jefferies LLC, dated March&nbsp;17, 2023, as amended from time to time or (G)&nbsp;any assistance to a stockholder of the Company in the establishment of a trading plan by such stockholder pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Stock; provided (x)&nbsp;that such plan does not provide for the transfer of Stock during such <FONT STYLE="white-space:nowrap">30-day</FONT> period pursuant to the
terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement between such stockholder and the Underwriter in connection with the Offering (the <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), (y) the establishment of
such plan does not require or otherwise result in any public filing or other public announcement of such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period and (z)&nbsp;such plan is otherwise permitted to be implemented during
the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Use of Proceeds.</I> The Company
will apply the net proceeds from the sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization.</I> Neither the Company nor its affiliates will take, directly or indirectly,
without giving effect to Shares offered by the Underwriters, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange Listing.</I> The Company will use its best efforts to list, subject to notice of
issuance, the Shares on the Nasdaq Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Reports.</I> During a period of three
(3)&nbsp;years from the date of this Agreement, the Company will furnish to the Representative, as soon as commercially reasonable after the date on which they are available, copies of all reports or other communications (financial or other)
furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have
furnished such reports and financial statements to the Representative to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good
faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>Shelf Renewal.</I> If immediately prior to the third anniversary (the &#147;Renewal
Deadline&#148;) of the initial effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new
automatic shelf registration statement relating to the Shares, in a form satisfactory to the Representative. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has
not already done so, file a new shelf registration statement relating to the Shares, in a form </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The Company will take
all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall include such new
automatic shelf registration statement or such new shelf registration statement, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;It has
not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free writing prospectus&#148;, as defined in Rule 405 under the
Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free
writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in a previously filed Issuer Free Writing Prospectus,
(ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(b) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and
approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii) an &#147;Underwriter Free Writing Prospectus&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;It has not and will not, without the prior written consent of the Company, use any free writing
prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided </I>that Underwriters may use a term sheet substantially in the form of Annex
B hereto without the consent of the Company; <I>provided further</I> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrent with, the first use
of such term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;It is not subject to any pending proceeding under Section&nbsp;8A of the
Securities Act with respect to the offering contemplated by this Agreement (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Shares on
the Closing Date as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the
Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus
shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all
requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representative. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations and Warranties.</I> The
representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date ; and the statements of the Company and its officers made in any certificates delivered pursuant to this
Agreement shall be true and correct on and as of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Adverse
Change.</I> No event or condition of a type described in Section&nbsp;3(h) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the
Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representative makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date on the
terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Officers&#146; Certificate.</I> The Representative shall have received on and as of the Closing
Date a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representative (i)&nbsp;confirming that such officers have carefully
reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(a) and 3(e) hereof are true and correct, (ii)&nbsp;confirming that the other
representations and warranties of the Company in this Agreement are true and correct and that the Company has complied in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or
prior to the Closing Date and (iii)&nbsp;to the effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Comfort Letters.</I> (i)&nbsp;On the date of this Agreement and on the Closing Date
Deloitte&nbsp;&amp; Touche LLP shall have furnished to the Representative, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the
Representative, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial information contained or
incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date
no more than two business days prior to such Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion and Negative Assurance
Letter of Counsel for the Company.</I> Goodwin Procter LLP, counsel for the Company, shall have furnished to the Representative, at the request of the Company, their written opinion, including with respect to certain regulatory matters, and negative
assurance letter, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion of Intellectual Property Counsel for the Company</I>. Marshall, Gerstein&nbsp;&amp; Borun
LLP, intellectual property counsel for the Company, shall have furnished to the Representative, at the request of the Company, their written opinion, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion and Negative Assurance Letter of Counsel for the
Underwriters.</I> The Representative shall have received on and as of the Closing Date an opinion and negative assurance letter of Cooley LLP, counsel for the Underwriters, with respect to such matters as the Representative may reasonably request,
and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Legal Impediment to Issuance and Sale.</I>
No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date prevent the issuance or
sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date prevent the issuance or sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Good Standing</I>. The Representative shall have received on and as of the Closing Date
satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representative may reasonably request, in
each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange Listing.</I> The Shares to be delivered on the Closing Date shall have been approved for
listing on the Nasdaq Market, subject to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and all executive officers and directors of the
Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional Documents.</I> On or prior to the Closing Date the Company shall have furnished to the
Representative such further certificates and documents as the Representative may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates
and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each
Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses,
claims, damages and liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint
or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement
thereto), any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including
any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with
any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in subsection (b)&nbsp;below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of the Company.</I> Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of
the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities (including, without limitation, reasonable and
documented legal fees and other expenses incurred in connection with any suit, action, or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration
Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any
Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the
Prospectus furnished on behalf of each Underwriter: the information in the first and second paragraphs under the heading &#147;Underwriting&#151;Commission and Expenses,&#148; the information in the second, third and fourth paragraphs under the
heading &#147;Underwriting&#151;Stabilization&#148; and the information under the heading &#147;Underwriting&#151;Electronic Distribution.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or
regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;9, such person (the &#147;Indemnified
Person&#148;) shall promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any
liability that it may have under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>,
<U>further</U>, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;9. If any such proceeding shall
be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of
the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the
fees and expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person
has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in
addition to those available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the
same counsel would be inappropriate due to actual or potential differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be
liable for the reasonable and documented fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such reasonable and documented fees and expenses shall be paid or reimbursed as
they are incurred. Any such separate </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by Jefferies LLC and any such separate firm for the
Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence,
if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be
liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not
have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened
proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such
Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault,
culpability or a failure to act by or on behalf of any Indemnified Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Contribution.</I>
If the indemnification provided for in paragraphs (a)&nbsp;and (b) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such
paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that
resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same
respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set
forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and
equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed
to include, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subject to the limitations set forth above, any reasonable and documented legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding
the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the
offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs
(d)&nbsp;and (e) are several in proportion to their respective purchase obligations hereunder and not joint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in
this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representative, by notice to
the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date: (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or the Nasdaq Market;
(ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general
moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or
crisis, either within or outside the United States, that, in the judgment of the Representative, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date on
the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If, on the Closing Date any Underwriter defaults on its obligation to purchase the Shares that it
has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the terms
contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to
a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree to purchase
the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in order to effect any changes that in the opinion
of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the
Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in
Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for
the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain
unpurchased on the Closing Date does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that such
Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date exceeds <FONT
STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement shall terminate without
liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will
continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the
Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is
terminated, the Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and
delivery of the Shares and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, any Issuer Free Writing Prospectus, any Pricing Disclosure
Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the reasonable and documented
fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the Representative may
designate and the preparation, printing and distribution of a Blue Sky Memorandum and any &#147;Canadian wrapper&#148; (including the related reasonable and documented fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of
preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering by FINRA; (viii)&nbsp;all
expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors, provided however, that the Underwriters will pay all of the travel, lodging and other expenses of the Underwriters or any of their
employees incurred by them in connection with the &#147;road show&#148;, and provided, further, that the Company and the Underwriters will each pay 50% of the cost of any aircraft chartered to be used in connection with such road show by both the
Company and the Underwriters; and (ix)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Market; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If (i)&nbsp;this Agreement is terminated pursuant
to Section&nbsp;9, (ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters (other than by reason of a default by any Underwriter) or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason
permitted under this Agreement, the Company agrees to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their
counsel) reasonably incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon
the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or
shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely
by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers,
controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Defined Terms</U>. For
purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day
on which banks are permitted or required to be closed in New York City; (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act; and (d)&nbsp;the term &#147;significant subsidiary&#148; has the meaning
set forth in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. In the event that the Company has only one subsidiary, then all references herein to
&#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, mutatis mutandis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of
Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which
information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be
deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representative c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022,
Attention: Global Head of Syndicate. Notices to the Company shall be given to it at Akero Therapeutics, Inc., 601 Gateway Boulevard, Suite 350, South San Francisco, California 94080; Attention: President. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related
to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Waiver of Jury Trial</I>. Each of the parties
hereto waives any right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in
this Section&nbsp;16(g): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81,
47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts
delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic
signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law, e.g., www. Docusign.com) or other transmission method any counterpart so delivered shall be deemed to have been duly and
validly delivered and be valid and effective for all purposes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments or Waivers.</I> No amendment or
waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings.</I> The headings herein are included for convenience of reference only and are not
intended to be part of, or to affect the meaning or interpretation of, this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Integration. </I>This Agreement supersedes all prior agreements and understandings (whether
written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page
Follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AKERO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Cheng</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Andrew Cheng, M.D., Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For themselves and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Brinkman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Michael Brinkman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,238,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,238,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Significant Subsidiaries </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Akero
Securities Corporation </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Base Prospectus included in the Registration Statement </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Public Offering Price: $42.00 per Share </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Shares: 5,238,500 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Akero Therapeutics, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Akero Therapeutics, Inc. &#151; Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a
director, officer or securityholder of Akero Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), understands that you, as representative (the &#147;Representative&#148;) of the several Underwriters, propose to enter into an
Underwriting Agreement (the &#147;Underwriting Agreement&#148;) with the Company, providing for the offering (the &#147;Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of
common stock, par value $0.0001 per share (&#147;Common Stock&#148;) of the Company (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Offering of the Securities, and for other good and valuable
consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of Jefferies LLC on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect
affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of business 30 days after the date of the final prospectus supplement relating to the Offering (the
&#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,
hedge, lend or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other
securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant), (2)
enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described in clause
(1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise (3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock (and, for the avoidance of doubt, the undersigned hereby waives any and all notice requirements and rights with respect to the registration of any securities pursuant to any agreement,
instrument, understanding or otherwise, including any stockholders or registration rights agreement or similar agreement, to which the undersigned is a party or under which the undersigned is entitled to any right or benefit) or (4)&nbsp;publicly
disclose the intention to do any of the foregoing, in each case other than: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Securities, if any, to be sold by the undersigned pursuant to the Underwriting Agreement,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sales or transfers of shares of Common Stock acquired in open market transactions after the consummation of the
Offering, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of Common Stock (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;by will, other
testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned in a transaction involving a disposition for value or (iii)&nbsp;by operation of law, such as
pursuant to a qualified domestic order or as required by a divorce settlement, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is an individual, transfers of shares of Common Stock or any security directly or indirectly
convertible into Common Stock in a transaction not involving a disposition for value to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or limited partnerships the partners of which are the
undersigned and/or the immediate family members of the undersigned, in each case for estate planning purposes, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a trust, distributions of shares of Common Stock or any security directly or indirectly
convertible into Common Stock to its beneficiaries in a transaction not involving a disposition for value, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a corporation, limited liability company, partnership (whether general, limited or
otherwise) or other entity, distribution of shares of Common Stock or any security directly or indirectly convertible into Common Stock to current or former members, stockholders, limited partners, general partners, subsidiaries or affiliates (as
defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or to any investment fund or other entity that controls or manages the undersigned (including, for the avoidance of doubt, a fund managed by the same
manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company as the undersigned or who shares a
common investment advisor with the undersigned) in a transaction not involving a disposition for value, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of Common Stock to the Company in connection with the exercise of options, warrants or
other rights to acquire Common Stock or any security convertible into or exercisable for Common Stock of the Company by way of net exercise and/or to cover withholding tax obligations in connection with such exercise pursuant to an employee benefit
plan, option, warrant or other right disclosed in the Prospectus, provided that any such shares issued upon exercise of such option, warrant or other right shall be subject to the restrictions set forth herein; <I>provided</I> that no public report
or filing required to be made under Section&nbsp;16(a) of the Exchange Act or other public filing, report or announcement shall be required or shall be voluntarily made during the period beginning on the date hereof and continuing to and including
the date that is 30 days after the date of the Prospectus (the &#147;30 Day Period&#148;), and after such 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day, if the undersigned is required to file a report under Section&nbsp;16(a) of the
Exchange Act during the Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that such transfer is pursuant to the circumstances described in this clause (G), and <I>provided</I>, <I>further</I> that no other public
announcement shall be made voluntarily in connection with such transfer; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(H)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of Common Stock to a bona fide third party pursuant to a merger, consolidation, tender
offer or other similar transaction made to all holders of Common Stock and involving a &#147;Change of Control&#148; of the Company after the Offering and approved by the Company&#146;s Board of Directors (with &#147;Change of Control&#148; meaning
the transfer of the Company&#146;s voting securities in one transaction or a series of related transactions to a person or group of affiliated persons if, after such transfer, such person or group of affiliated persons would hold more than 50% of
the outstanding voting securities of the Company (or the surviving entity)), provided that in the event that such transaction is not completed, the shares of Common Stock held by the undersigned shall remain subject to the restrictions contained in
this Letter Agreement, and provided further that in the event any shares of Common Stock not transferred in the Change of Control shall remain subject to the restrictions contained in this Letter Agreement; [and] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[the transfer of shares of Common Stock under a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a &#147;Trading Plan&#148;) that is existing on the date hereof which has been provided to the Representative or its legal counsel; provided, that, to the extent a public
announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding such transfer, such announcement or filing shall include a statement that such transfer is in
accordance with an established Trading Plan;]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U>
that in the case of any transfer or distribution pursuant to clause (C), (D), (E), (F) or (G)&nbsp;each donee, transferee, heir, beneficiary or distributee shall execute and deliver to the Representative a
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and <U>provided</U>, <U>further</U>, that in the case of any transfer or distribution pursuant to clause (B), (C), (D), (E), or (F), no filing by any party
(the undersigned, beneficiary, heir, donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended, (&#147;the Exchange Act&#148;) or other public announcement shall be required or shall be made voluntarily in
connection with such transfer or distribution (other than a filing on a Form 5 and any required Schedule 13F, 13G or 13G/A, in each case made after the expiration of the Restricted Period referred to above). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or
arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined)
designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or
indirectly, of any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or
any securities convertible into or exercisable or exchangeable for Common Stock, in cash or otherwise. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[NTD: To insert only for those individuals with trading plans in place.] </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Letter Agreement, the undersigned
may (i)&nbsp;exercise options or warrants to purchase Common Stock of the Company pursuant to employee benefit plans or arrangements disclosed in the Prospectus (provided that (a)&nbsp;any Common Stock received upon such exercise or exchange will be
subject to the restrictions provided for under this Letter Agreement and (b)&nbsp;if the undersigned is required to file a report under Section&nbsp;16(a) of the Exchange Act during the Restricted Period, the undersigned shall clearly indicate in
the footnotes thereto that such transfer is pursuant to the circumstances described in this clause) and (ii)&nbsp;enter into any plan designed to satisfy the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> (a <FONT
STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;) under the Exchange Act (other than the entry into such a plan in such a manner as to allow the sale of Common Stock within the Restricted Period); provided, however, that no sale of Common
Stock may be made under such <FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan during the Restricted Period, and provided further that no filing by any party under the Exchange Act or other public announcement shall be required or shall be made
voluntarily in connection with establishment of such plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Letter Agreement, (i) &#147;immediate family&#148; shall
mean any relationship by blood, marriage or adoption, not more remote than first cousin and (ii) &#147;change of control&#148; shall mean any bona fide third-party tender offer, merger, consolidation or other similar transaction, in each case, the
result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT>
and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of a majority of total voting power of the voting stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further
acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the Representative and the other Underwriters are not
making a recommendation to you to enter into this Letter Agreement and nothing set forth in such disclosures is intended to suggest that the Representative or any Underwriters is making such a recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that (i)&nbsp;if the Underwriting Agreement does not become effective by June&nbsp;30, 2023, (ii) if the
Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, (iii)&nbsp;if the Representative, on the one hand, or
the Company, on the other hand, informs the other in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering, or (iv)&nbsp;prior to execution of the Underwriting Agreement, if the
Company files an application with the SEC to withdraw the registration statement related to the Offering, then the undersigned shall be released from, all obligations under this Letter Agreement. The undersigned understands that the Underwriters are
entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page
Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Security Holder <I>(Print exact name</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:_______________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title of Authorized Signatory <I>(Print</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Lockup Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d503970dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;5.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g503970goodwin.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Goodwin&nbsp;Procter&nbsp;LLP<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">100&nbsp;Northern&nbsp;Avenue</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Boston,&nbsp;MA&nbsp;02210</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">+1&nbsp;617&nbsp;570&nbsp;1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;17, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Gateway Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re:&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-256229)</FONT> (the &#147;Registration Statement&#148;) filed and deemed effective on May&nbsp;18, 2021 with the Securities and Exchange Commission (the &#147;Commission&#148;) pursuant to the Securities Act
of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration of the offer by Akero Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), of any combination of securities of the types specified therein. Reference
is made to our opinion letter dated May&nbsp;18, 2021 and included as Exhibit&nbsp;5.1 to the Registration Statement. We are delivering this supplemental opinion letter in connection with the prospectus supplement (the &#147;Prospectus
Supplement&#148;) filed on May&nbsp;17, 2023 by the Company with the Commission pursuant to Rule&nbsp;424 under the Securities Act. The Prospectus Supplement relates to the offering by the Company of 5,238,500 shares of the Company&#146;s common
stock, par value $0.0001 per share (the &#147;Shares&#148;), covered by the Registration Statement. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters
(the &#147;Underwriting Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the
opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the
Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the
opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under the caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit
that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akero Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;17, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter LLP</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GOODWIN PROCTER LLP</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d503970dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g503970g0517054629596.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA &#150; May&nbsp;16, 2023 &#150; Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational
treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting
discounts and commissions, for total gross proceeds of approximately $220.0&nbsp;million. All of the shares to be sold in the offering are being sold by Akero Therapeutics. The financing was led by new investor General Atlantic and included existing
investors Adage Capital Partners LP, Avidity Partners, Boxer Capital, Commodore Capital, Janus Henderson Investors, Logos Capital, Perceptive Advisors, Rock Springs Capital and funds and accounts advised by T. Rowe Price Associates, Inc.&nbsp;The
offering is expected to close on or about May&nbsp;19, 2023, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies is acting as sole
book-running manager for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock are being offered by Akero Therapeutics pursuant to an automatic shelf registration
statement on Form <FONT STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256229)</FONT> that was previously filed with the U.S. Securities and Exchange Commission (SEC) on May&nbsp;18, 2021 and
automatically became effective upon filing . The prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC&#146;s website at www.sec.gov. Copies of the prospectus
supplement and accompanying prospectus may also be obtained, when availbale, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) <FONT
STYLE="white-space:nowrap">821-7388;</FONT> or by email at prospectus_department@jefferies.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Akero Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical
need, including <FONT STYLE="white-space:nowrap">non-alcoholic</FONT> steatohepatitis (NASH), a disease without any approved therapies. Akero&#146;s lead product candidate, efruxifermin (EFX), is a differentiated
<FONT STYLE="white-space:nowrap">Fc-FGF21</FONT> fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the
body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of observed effects position EFX to be a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with <FONT
STYLE="white-space:nowrap">pre-cirrhotic</FONT> NASH <FONT STYLE="white-space:nowrap">(F2-F3</FONT> fibrosis), and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). EFX is also being evaluated in an expansion cohort of
the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist in patients with <FONT STYLE="white-space:nowrap">pre-cirrhotic</FONT> NASH <FONT
STYLE="white-space:nowrap">(F1-F3</FONT> fibrosis) and Type 2 diabetes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including,
without limitation, statements regarding the closing of Akero&#146;s anticipated public offering. The words &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;target&#148; and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#146;s current expectations and
beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market conditions and statements regarding the timing, size and expected gross proceeds of the offering, the satisfaction of customary closing conditions related to the offering and sale of
securities, and Akero Therapeutics&#146; ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled &#147;Risk Factors&#148; in Akero&#146;s most recent annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Akero&#146;s other filings
with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering to be filed with the SEC. Any forward-looking statements contained in this press
release represent Akero&#146;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Akero explicitly disclaims any obligation to update any forward-looking statements, except as required
by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina Tartaglia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212.362.1200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@akerotx.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sarah O&#146;Connell </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">732.456.0092 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>soconnell@vergescientific.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>akro-20230516.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 5/18/2023 12:56:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:akro="http://www.akerotx.com/20230516"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.akerotx.com/20230516"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akro-20230516_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akro-20230516_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>akro-20230516_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 5/18/2023 12:56:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>akro-20230516_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 5/18/2023 12:56:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="akro-20230516.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g503970g0517054629596.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g503970g0517054629596.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- JH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HJO?W1L=.N;L02W!@B:3R80"[X&<+GN:\EN_BQXTCLWU:+X=72:2B[S)-*
MP?9_>(V\#'.<$4 >D^(?%6B>%+:&YUN_6SAF?9&S(S;FQG'R@]JUHI4GA2:-
MMT<BAE;U!Y%?/'Q?\6V7C7X9:!K%BCQJ]^\<D3\M&XC.5)[]CGT(KN=?^*4?
MAY]'\.Z)IS:UKTT42M:QOM$64& QP?F[X[#DXH ]1HKSKQ-XS\;:#-8P6G@I
MM4DEMA+</:2.T<4A8@H#MYP .>.M5?#_ ,0?&FI:Y;VFI^ KK3K*3=YMTY?;
M& I(SE0.2 /QH ]/HKP_3?CY?:KI[1V'A2:]UEI2([2U=G41@#YV(7/4XP!V
MZBMO7?C!/'X@?P_X6\/3ZYJ4 _T@QL0D;#[P& 2<'@DX&>.: /5:*\T\(_%K
M^U_$?_"-^(M%GT/6&_U4<K$K(<9QR 02.G4'UKTN@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g503970goodwin.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g503970goodwin.jpg
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M9+@QVROE?,?&)^K3\^L\Y?*D#1 R0.[TH/_$ $ 0  $"! ,#!0T%"0
M  $" P $!1$2(3$&$$$3(E%AD10@,C- 0G%R<X&AL<$E-%)BT0<5(R1#4X.R
MPO_:  @! @ !/P%UUME!6ZH(0.)BH[62\O=$FCEUCSCD@?4^BT5"MU:=5=<T
MIM(T2T>32.S6*?M55J:0E;G=C%_ =.8]56L4O:ZF3^%MPF4?.6%?@GU5?K:
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M?I3_Q  F$ $  @(" 0,$ P$        !$2$ 03%181!Q@4"AL='!\/&1_]H
M" $!  $_(8RJ$KY3D*YJ-S2$/^RT\@U3]F4/O:QT>38&?)\\##[  0G4 1*=
M%NC)^HEHX7'$*1YZ?.)9\;$$%,RD"5#HY+)#DG".#&TR?+.('<H4T8/8#SEQ
M^S(B:SU7+6#@E-=4,*SLB?5*H 44"U> 1B0R3"FF8@MLUQ@ICB@@2@I1PF(#
M0$J]!;]LC4G#Y8=C:C#HN#EN*!#9G&<")WOQ8WA1 XKS^P<<&*"PE !5  ]
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M*T3>6U_2UCI<XF(;*V0^[O-#U/US/]?XG\C_Q  E$ $  @(" @$$ P$
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MDLBZM5M(<U%;I4=P"0\  78#!D/IKQ46.T$ [Q,_/J,C$\P+ELF3/RF*&EU
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..L$;?,L]5->*FO'Y'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139812770513744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 16, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001744659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 16,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Akero Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5266573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Gateway Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">487-6488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AKRO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d503970d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="akro-20230516.xsd" xlink:type="simple"/>
    <context id="duration_2023-05-16_to_2023-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001744659</identifier>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-05-16_to_2023-05-16">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-05-16_to_2023-05-16"
      id="Hidden_dei_EntityCentralIndexKey">0001744659</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-05-16_to_2023-05-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-05-16_to_2023-05-16">2023-05-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-05-16_to_2023-05-16">Akero Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-05-16_to_2023-05-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-05-16_to_2023-05-16">001-38944</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-05-16_to_2023-05-16">81-5266573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-05-16_to_2023-05-16">601 Gateway Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-05-16_to_2023-05-16">Suite 350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-05-16_to_2023-05-16">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-05-16_to_2023-05-16">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-05-16_to_2023-05-16">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-05-16_to_2023-05-16">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-05-16_to_2023-05-16">487-6488</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-05-16_to_2023-05-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-05-16_to_2023-05-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-05-16_to_2023-05-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-05-16_to_2023-05-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-05-16_to_2023-05-16">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-05-16_to_2023-05-16">AKRO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-05-16_to_2023-05-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-05-16_to_2023-05-16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "&(L58'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  AB+%6AVZO8>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OIW]0(71S43PI""XHWL)D=C?8-"$9:??M3>MN%]$'$'+)S"_?
M? /I,$CTD9ZC#Q394KJ:7#\DB6$C#LQ! B0\D-.IS(DA-W<^.LWY&O<0-'[H
M/4%353?@B+71K&$&%F$E"M49E!A)LX\GO,$5'SYCO\ , O7D:. $=5F#4//$
M<)SZ#BZ &<847?HND%F)2_5/[-(!<4I.R:ZI<1S+L5UR>8<:WIX>7Y9U"SLD
MU@-2?I6LY&.@C3A/?FWO[K</0C55TQ;5=5'?;IM:5O-YGUU_^%V$G3=V9_^Q
M\5E0=?#K7Z@O4$L#!!0    ( "&(L5:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M+=)#,!"D/*N^Z?MA((X#O!,!WB' *[FK%Y64MU33R4B*'9'F:5 S%V57RVB
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( "&(L58'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ (8BQ5H=NKV'M
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ (8BQ5IE<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  AB+%6$8V0*6\$  ! $0
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ (8BQ5I^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  AB+%6EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    "  AB+%6'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ (8BQ5B0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ (8BQ5F60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d503970d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d503970d8k.htm">d503970d8k.htm</File>
    <File>akro-20230516.xsd</File>
    <File>akro-20230516_lab.xml</File>
    <File>akro-20230516_pre.xml</File>
    <File>d503970dex11.htm</File>
    <File>d503970dex51.htm</File>
    <File>d503970dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d503970d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d503970d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "akro-20230516_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "akro-20230516_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "akro-20230516.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "akro",
   "nsuri": "http://www.akerotx.com/20230516",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d503970d8k.htm",
      "contextRef": "duration_2023-05-16_to_2023-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d503970d8k.htm",
      "contextRef": "duration_2023-05-16_to_2023-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.akerotx.com//20230516/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-23-147097-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-147097-xbrl.zip
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ML^VX]K:K5S?%;'.,VYO^N#=7S;JAG[\ 4$L#!!0    ( "&(L58+FCJ/? 8
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M#G>>%?BPY(FEB9 %@C_@L!CYSIA')Q $EWT:SF(+-8AU?JG]&_#PD^LQN#<
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MUE!/!5.#T0]51+44))118-03!H680%&%\:Q[&*5O$D>%DS24?AT%RL>[*CR
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M7=<B$U."TK6U5/4]28%-\2EU6"Z! MQ?$C 0.5:LIDKKE(.2+.7*E#35]XQ
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MP:PS)+5VI^I*G9'+AH".XE?07JM7T(I%;7P<:Q]7]*\>J]]$/OE_4$L#!!0
M   ( "&(L5;#_ES'\J$  &XD P 0    9#4P,SDW,&1E>#$Q+FAT;>R]Z7(<
MQY(N^!]F>(<TW>YK@%F" D!2&]4T@TA*XCV41".I/MTS-C^RJK* %+,R2[D
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M(.LK68+5E8D5"E,U#[H'6SH?W=+7R8;NU&49++<S/,GQG^%]#VL*-V=1XWK
MLF<K,-)PPG@.76!@V9(\\&E.YO.R16<;CTRVS'P$PH29^%H.DRF\%[#T<!HE
M457FZ29Z]>IU'.$S82_<B.V6Q?C;QX^C7]L%IGW_.ZD6M;^]PKSL\<G1Z<GC
M;^DG)\<_'!]'9V-W711<==\+5 +>#S^E$RXI)PKT8&('_"/X#7B<E!OC3\T7
MT1Z/27-A+%!R561Y94L0ZEE;9Q0?6B0;-G/)EG?>3#_W%"PJBBW)-8=I8*_$
ME.&S0*/$WZC/1 -;=^3 K2J<81>3W!X#?0:GCZS!Y_!PC=]=/Z=SN]*_N*[T
M2VQ9;H6%*A^97(1SZYR0Y#S)BKI!YR6'/:G&1%M?9*X1.27N2AV\L4/[96!\
MM(G! ,E"IT.FI[9)/L"/8:?IJ Y$WAJ3RJ4'ROO@AMK [[+N^7V :7V:+EB#
MRW']H8J21#R9@Z(D P%^@@+Y/*7+LH1%>U>U=>/3V"Q3S]\]\XFPG..FO87E
M%]+QNLIJG!VG11Y\"99]DC.5[F:H;KEO]_=&=!GKR=!H]8B,&FX#D$BY_.?)
M&F2JV<C-FU0KM;+RM#CG@#*< ?#@X%3164LKS!NY,ZJC'0K@6)-%9)LR]:LU
MIW$D46Y<TH%SM4C1;LDT(P[W IDQ<F3T%8?.GL7X"]P%15+,,T0(+"ZSNB3,
M 'Z\:.%3TC Q?013/J>4ZS+TZ^EO&UE*,('A1GP0G3DD!=K+A8$F=':B"'YN
M=@*O 1J1^M\3[Z/+H:2/\_0\R<%K!"6$F8;+M&[$V6#]1VM<:7 )E<$J:<2.
MI ?\!8YTO<AH64.KCL\^+'K=Y@).P)1*>57HT@68!-)L^G"R[%19X=[#4S*R
M9"CK\9YV5!Z&AV6=THF1&63G'$H@T5ZOJR0#]:G[2GHWH?&">S4@->QH;=F#
MD=-@PE@<RY21HVZEK0!C5/XQ*>7J=7"H^S*#(RXZ?O>3&2*')&AK9S]X9%"@
MZ5FZ%38_ST$X^XBKC/<(! OC3/ <T0)ZI<[2(EUF+AL<Z@ZWRWB\$-=4P/_"
M!\O.X.\@@O=P&H(2^-<TD7]Z%SL<O$.FN+UV[CG_4IQS.I-=_YYT\@]X4=ZM
ML38> ?GQY=-Q/^_'KU_*W,>_8[(0W1CI(@,/%&1#L@-^94.+B@4H)GE.1"^!
M[JK:U$)?X!I"H0:E#LH [!T*T6*:ER0;O]?[ EP78-B@5H>GEM6"0_SD-Y-1
MI@^O->SMLK4Y(KEUN/.LFK<K],K1<>(PY-5%-B?3"XX^0NK0(B/G8W]OE=5Y
MFN"M!4;ZGT\U)H1RY%UB[U:\AV<692?F@W,3N>K?H*2=_=AY&2A/4+-EF&$:
M&505QFC)6^&L!N6 X91G^DP;7+9Z E]@A7C9@HZO+]A!L:/W7A#H-TQ[]Z3?
MFZ@=S9=^P'_6HFI:,BY908V+6LS8&/RC!$K*<N$MH(5?WK* !]/3[!S]/&:;
MWB3QILMJ[S'8'R[2>EYELW3!R7]Z[/[>6[9&^!Q]BWENE*)R^2#ZO0PE-Q3+
M+M#!9*LPXSY+P3E$P4:U[L)E4P>0#)SKO7'T8;2$Y),24LMDC/0)[(!/#9I.
M$XY\*G!]UV$W4'PO,<Y;13^C5_]/D>,P[_3RZ1^-XEYYWCNGK4*ST9JRA/IT
MUT>(@HXMT'8@^(>?996WSD4>#VD3\!K6G%,L*@FS=J!_V^:BK#"9%Y-)55ZB
M@]L!#>%=)LI8'Q.3@HH)IF>>XA[BGJ%J@YU+#7$@%KLMX$KPJ*\@<0;SV2&]
M0R*)Q[/)FK8AGT=#F24'$#$05,+5DZGV7 ;?F;4;ZT8?T"U-QS@88#>.AO#$
MR<V*#LQF)9V'V:5%W9LGJ.0.,A%(SAGB,'G)IF51777S/O<DFZ:FO7-+U45K
M!I"$0'N=@H5P<')\B$ NASCOH&(K01X]?#0!G:U@7#JP,(TXEJ2+V6A*,0M:
ME;!\454F:%B65PY4P-,>E*K:R[.YC3)R4N@"'#2\'T0OG R8E=_?ZR\]O@[,
M&D8/$OI<5:M<R?4@))D &EXS5L[4/L!OBQZFJ"'8WAE<8SZ<ZT[%PX>' CO
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MYDF>K$B&.P*@'L8,E2"H+E3:=);IL33!9"8JI:UFK-/IG^NV2?70LZC%FG'
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M+K"Y+&(S!,I7+66FX$R!"%*?C"]1U-N(HLZ)]4?K,RZ2:@6.-EU?N][BB 1
M1C%Z-H$65BZ5Y[S7=!%ZNI:A6&A0,>](3HYD("5]%X>.;\W-W;Q/3 3+QC88
MRPXZ0<38S3FCB)D3OBU;TRP*[[U%6R #"\_:D6T)",%(*E[GJ*>,58#?> OJ
M)B.+\#G]U?5;@8O_ZA >*'\.76X#*$SUN<JZ9+Z%CQ1%LK_72D!X +\,2^&S
M@9;NQ;L'<&]Q80-^P=FB".9NF^2<[=7NQ28,VU3 1'E&=/Z25=J!G#MTA7\;
MNB<+=4:01=$84#7WK; L_L[]:[@E]Y(AF"2G5&=:XUYI52[VT%J0]\,1ODSH
MK3#IDZ57G &TP-XNYR!-XNXQ2/^:K!2'K:>\QV4BLOE69?,5U?WL9'KOG&D.
MG9ODW'G \#AUI$H*<E;2$TY4@;#_T.2P;V+,(HJ^:")]9R;Z'!-'3 >S'^_O
M+=,%=E&+Q5FF[=5":#PK:[,L]($[MPCR#\"BL<#?^*190)QUKOV9[M-^TN+]
MFB9Y@T%0:740O2ZK1B48GZ=00_GHC)/V)]]__XU31K^^?/?BV:_TI\" 4-OA
MUY>OSWQM _[B18O>>5)@B *;+W%S.=8TKUD3XN>F/Y-VD'O^^HU:( <O_HQ.
MCT^^^?J;;[\?,ET$LJ"BAM+E&:W+*%D0%L7NJ0OPV-_$VRT4T@\9,>K-4T*I
MN!Y3HK2PD:?/!>2;P7 I*+$L=='L':2,Y5LO'/48Y,X)E$-/NIQ@^2)87CXA
MB*^H(I( 1#:\>@%?E[HG_)VC95S"D5:P'=\79@-D?&[QY6/[?:'[6Z7H^?C*
MM@B.1XN2P:I2CWA!NAH,N12;]BP$4]2D>;J^P/ 0D\GM$)1,C^ 6SGWO/GD2
M/*4IS^$;%VC@,YF:KI<2U8%N2#Z MT=7FJOBTC<OL'U<I>,5X]W]=9W4-?;L
M<Q^ ][[(FFB.07'];)84[T-WT0$!A B33Z;\X$E0?*X4F>LL921&X&50PE\&
MKLT9PI5F.?==UJ2;$"^0<!C;0_(@.C,6U*Y'AB&(\"O;NXYQ:QQUTNF&,5*C
M6,.#*M0ZIC.S>2[C&JL^0<-K)HG#$6UWFX6!*2L2I*$0S-%0E&YDD.'=IHV5
M%98MH-2#I-.-!V1#C003',2;"I,#L.0&@')!$66!X\A_."[%$)JC0434(8V8
M9LY^"?@D9VW#."RZ/MC;\C9E%>H7M<>\21X88%P++J1H9($1 I@"#EQ$OL!
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M[27R#2<:(NM*^O@P'@ _QQWB);"V&?41N_K^.O8Y#M-I6K+OV-07*9-L2Z^
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M9&5X-3$N:'1MS5E;<^HX$GY/%?^AB]F9FJGE3JZ$4,7M)%210 'G9&??A"U
M>VS+:]GAL+]^NR49#"%,I2;9V3PD6$A]_?KKMM)\F#T.6\V'?KO7RITU9X/9
ML-_J_Z-X4:HVR^8)E\OV>VAV1KW?H7/?'0U'D[O\\\-@UL^W('>&F[H\B'G4
M:O8&WV Z^WW8O\NOA1NO&M>E"Q'D@7EB&=SE/;Z(\UK6.-WFLV@I@F(LPT8E
MC&_!/L]E'$O?+"UD$!>5^ ]O5'?/"^8+;].8"9\K>.)KF$B?H:;V<'#_=)>/
MQ'*%JIJ=5O_'2LQ%_$LP5^$MN@;-<J?5+(_)MZT5&14U5'%@U"N;\BTCCL0
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MQRY2#47#<:YNENE?6[BH_R'V7U!+ P04    "  AB+%6P,)/6VP,  "8(P
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MHOL_<OX+4$L! A0#%     @ (8BQ5EUS?+M  P  2@L  !$
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M,&1E>#$Q+FAT;5!+ 0(4 Q0    ( "&(L59<%-\L\P<  !<;   0
M      "  8O'  !D-3 S.3<P9&5X-3$N:'1M4$L! A0#%     @ (8BQ5L#"
M3UML#   F",  !$              ( !K,\  &0U,#,Y-S!D97@Y.3$N:'1M
64$L%!@     '  < O $  $?<      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
